Third Quarter Financial Statements
We are pleased to present the un-audited Financial Statements of Beximco Pharmaceuticals Ltd. for the third quarter ended 30 September 2009 in terms of Securities and Exchange Commission Notification No. SEC/CMRRCD/ 2008-183/Admin/03-34 dated September 27, 2009:

Beximco Pharma Donates Oseflu (Oseltamivir) capsule to ICDDR,B for Swine Flu treatment
Leading drug manufacturer Beximco Pharmaceuticals Ltd. (BPL) yesterday (September 13, 2009) donated 5000 pcs. of Oseflu (Oseltamivir) capsule to ICDDR,B as a gesture of BPL’s support for the swine flu affected community of the country. This donation was a part of BPL’s ongoing CSR activities as a response to this major public health problem.

Price Sensitive Information
This is for information of all concerned that the Board of Directors of Beximco Pharmaceuticals Ltd in its meeting held on 2 September 2009 at 5-00 PM reviewed the situation arising out of the imposition of lock-in on shares and warrants issuable to GEM Global Yield Fund Limited and subsequent non-receipt of fund from them. In view of this, the Board in its aforesaid meeting has decided to issue upto 4,100,000 Fully Convertible, 5% Dividend, Preference Shares of Taka 1,000 each on the following terms and conditions subject to approval of the shareholders of the Company in their Extra-Ordinary General Meeting (EGM) to be held on 15 October 2009 (with Record Date on 17 September 2009) at 11 am at BEXIMCO Industrial Park, Sarabo, Kashimpur, Gazipur and SEC’s consent to the aforesaid Preference Share Issue:-

Beximco Pharma is first Bangladeshi company to receive GMP Certificate from National Health Surveillance Agency (Anvisa) of Brazil
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading Bangladeshi pharmaceutical manufacturer and largest pharmaceutical exporter from Bangladesh, is pleased to announce that it has received GMP Certificate for its facility from National Health Surveillance Agency (Anvisa) of Brazil. BPL is the first Bangladeshi company to receive this regulatory approval from Anvisa through a stringent facility audit process.

Beximco Pharmaceuticals exports Oseltamivir capsules to Latin and Central America
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”) today announces that it has commenced supplying Oseltamivir capsules, Oseflu® (BPL’s generic version of Tamiflu®), to Latin and Central American countries, the regions most affected by the recent H1N1 swine flu (influenza A) outbreak.

Nazmul Hassan MP appointed Managing Director of Beximco Pharmaceuticals
In a meeting of the Board of Directors of Beximco Pharmaceuticals Ltd (“BPL” or the “Company”) held on 7th May 2009 Mr. Nazmul Hassan was appointed Managing Director of the Company.

Audited Accounts 2008
We have audited the accompanying Balance Sheet of the Beximco Pharmaceuticals Limited as of December 31, 2008 and the related Profit and Loss Account, Statement of Changes in Equity and Statement of Cash Flows for the year then ended. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

PRICE-SENSITIVE INFORMATION
This is for information of all concerned that the Company’s Board of Directors in a Meeting held at its registered office at 17 Dhanmondi R/A, Road No 2, Dhaka-1205 on Monday, 26 January 2009, 9-15 AM made the following decisions:-

Beximco Pharma is first Bangladeshi pharmaceutical company to receive export approval to Gulf countries
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading pharmaceutical manufacturer and the largest pharmaceutical exporter from Bangladesh, announces the achievement of a milestone today following the receipt of approval from the Ministry of Health of Gulf Cooperation Council (GCC) countries for BPL to commence export of medicines into the GCC. BPL is the first company from Bangladesh to receive this approval.

Beximco Pharma is first pharmaceutical company from Bangladesh to enter Latin America
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading edge pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh has commenced exports to Chile, after receiving marketing authorization for a number of products from “Instituto de Salud Publica de Chile” (Drug Regulatory authority in Chile). With this, BPL has become the first Bangladeshi pharmaceutical company to obtain product registration in any Latin American country, a company statement said today.

Beximco Pharma is first Bangladeshi company to receive GMP Clearance from TGA Australia
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading Bangladeshi pharmaceutical manufacturer and exporter, is pleased to announce that it has received approval (GMP Clearance) from Therapeutic Goods Administration (TGA), Australia for its new Oral Solid Dosage (Tablet, Capsule), and the Metered Dose Inhaler and Spray manufacturing facilities. BPL is the first Bangladeshi company to receive this regulatory approval from TGA, Australia through a stringent facility audit process.

The Thirty-Second Annual General Meeting
Notice is hereby given that the THIRTY-SECOND ANNUAL GENERAL MEETING of the Shareholders of Beximco Pharmaceuticals Limited will be held on Thursday, the 21st August, 2008 at 10.30 a.m. at 1, Shahbag C/A, Dhaka to transact the following business :

Beximco Pharma awards Merit Scholarships
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading pharmaceutical manufacturer and exporter of Bangladesh, launched a ‘Merit Scholarship Scheme’ for the children of its factory employees, a company statement said today